Baili Tianheng Chairman Zhu Yi: China's Structural Edge in Innovative Drugs Is Being Globally Validated and Will Remain Competitive Over the Next Decade

Deep News11-13 17:31

At the roundtable discussion titled "From Following to Defining: Are Chinese Pharma Companies Becoming Global Innovation Leaders?" held on November 13 during the 2026 Shanghai Stock Exchange International Investor Conference, Sichuan Biokin Pharmaceutical Co.,Ltd. (688506) founder and chairman Zhu Yi stated that the structural advantages built up over the long term by China's innovative drug industry are being deeply understood and validated by the global market.

Zhu Yi noted that for a considerable period in the past, China's advantages in innovative drugs were first reflected in the emergence of individual innovative products, and later gradually evolved to the level of technology platforms. Over the past six months, however, the global market's understanding of China's innovative drug industry has deepened further. It is no longer limited to purchasing a particular product or technology platform, but has begun to recognize the structural advantages formed by China's innovative drug R&D system.

In his view, these advantages stem not only from the engineer dividend, but also from a complete industrial ecosystem. China possesses a vast patient population, a large number of professional researchers, and an efficiently operating R&D system. At the same time, the regulatory system continues to align with international standards, enabling innovative drugs to advance rapidly from early-stage research to clinical validation in accordance with globally unified norms and to generate data efficiently.

"Simply talking about the engineer dividend is not enough — it must be systematized," Zhu Yi emphasized. The combination of R&D talent, clinical resources, the regulatory system, and industrial organizational capability constitutes the unique competitive advantage of China's innovative drug industry. He compared this system to China's high-speed rail network, arguing that its advantages were not formed overnight and are difficult for other markets to replicate in a short period. The important change over the past six months is not that this advantage has just emerged, but that the global market has begun to truly recognize and acknowledge it.

Speaking about the application of artificial intelligence in innovative drug R&D, Zhu Yi pointed out that biology is highly complex. AI can generate a large number of molecular design solutions, but how to screen out the truly valuable molecules from among them remains a challenge. AI may also make errors when applying knowledge, and the R&D process must combine experimental verification with scientific judgment. He stressed that under conditions of limited resources, how to make AI play a more effective role and find optimal solutions will be an important issue that innovative drug R&D needs to address in the future.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment